Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1964;30(6):769–781.

Response of Volta children to live attenuated measles virus vaccine

Harry M Meyer Jr, Daniel D Hostetler Jr, Barbara C Bernheim, Nancy G Rogers, Paul Lambin, Albert Chassary, Joseph E Smadel
PMCID: PMC2555080  PMID: 14215184

Abstract

Experience so far with the Enders B-level Edmonston strain of live attenuated measles vaccine has been principally with children in the USA in whom natural measles carries a low mortality. Measles is associated with an appreciably higher mortality rate in developing countries; in Upper Volta, climate, nutritional status, degree of parasitic infestation and concurrent infections may contribute to this. The present report summarizes a pilot study in Ouagadougou, Upper Volta, designed to obtain information on the response of Volta children to Enders vaccine and to determine the feasibility of using this vaccine on a large scale.

The observations indicate that Volta children, despite the hazards of natural measles, respond in essentially the same manner to live vaccine given alone or with gamma-globulin as do children in other areas. The febrile reactions which characterize infection with the attenuated measles virus were of insufficient importance to warrant the concurrent use of gamma-globulin in a forthcoming mass measles vaccination campaign in Upper Volta.

Full text

PDF
769

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. COLLARD P., HENDRICKSE R. G., MONTEFIORE D., SHERMAN P., VAN DER WALL H. M., MORLEY D., GOFFE A. P., LAURENCE G. D., POLLOCK T. M. Vaccination against measles. II. Clinical trial in Nigerian children. Br Med J. 1961 Nov 11;2(5262):1246–1250. doi: 10.1136/bmj.2.5262.1246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. ENDERS J. F., KATZ S. L., HOLLOWAY A. Development of attenuated measles-virus vaccines. A summary of recentinvestigation. Am J Dis Child. 1962 Mar;103:335–340. doi: 10.1001/archpedi.1962.02080020347030. [DOI] [PubMed] [Google Scholar]
  3. ENDERS J. F., KATZ S. L., MILOVANOVIC M. V., HOLLOWAY A. Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination. N Engl J Med. 1960 Jul 28;263:153–159. doi: 10.1056/NEJM196007282630401. [DOI] [PubMed] [Google Scholar]
  4. ESCUDIE A., HAMON J. [Malaria in French West Africa]. Med Trop (Mars) 1961;21(SPECIAL):661–687. [PubMed] [Google Scholar]
  5. GANS B. Paediatric problems in Lagos. West Afr Med J. 1961 Feb;10:33–46. [PubMed] [Google Scholar]
  6. GIBBS F. A., ROSENTHAL I. M. Electroencephalography in natural and attenuated measles. Am J Dis Child. 1962 Mar;103:395–400. doi: 10.1001/archpedi.1962.02080020407045. [DOI] [PubMed] [Google Scholar]
  7. HALONEN P., FORSSELL P., HALONEN H., PETTAY O., STENSTROM R., OHMAN S., OKER-BLOM N. Clinical and immunological studies on a live attenuated measles virus vaccine in infants and children. Acta Paediatr. 1962 Jul;51:401–408. doi: 10.1111/j.1651-2227.1962.tb06562.x. [DOI] [PubMed] [Google Scholar]
  8. HILLEMAN M. R., STOKES J., Jr, BUYNAK E. B., WEIBEL R., HALENDA R., GOLDNER H. Ender's live measles-virus vaccine with human immune globulin. II. Evaluation of efficacy. Am J Dis Child. 1962 Mar;103:372–379. doi: 10.1001/archpedi.1962.02080020384038. [DOI] [PubMed] [Google Scholar]
  9. KATZ S. L., ENDERS J. F., HOLLOWAY A. Use of Edmonston attenuated measles strain. A summary of three years' experience. Am J Dis Child. 1962 Mar;103:340–344. doi: 10.1001/archpedi.1962.02080020352031. [DOI] [PubMed] [Google Scholar]
  10. KATZ S. L., MORLEY D. C., KRUGMAN S. Attenuated measles vaccine in Nigerian children. Am J Dis Child. 1962 Mar;103:402–405. doi: 10.1001/archpedi.1962.02080020414047. [DOI] [PubMed] [Google Scholar]
  11. KRUGMAN S., GILES J. P., JACOBS A. M., FRIEDMAN H. Studies with live attenuated measles-virus vaccine. Comparative clinical, antigenic, and prophylactic effects after inoculation with and without gamma-globulin. Am J Dis Child. 1962 Mar;103:353–363. [PubMed] [Google Scholar]
  12. MEYER H. M., Jr, BROOKS B. E., DOUGLAS R. D., ROGERS N. G. Measles serologic standards. Am J Dis Child. 1962 Mar;103:495–502. doi: 10.1001/archpedi.1962.02080020507071. [DOI] [PubMed] [Google Scholar]
  13. MORLEY D. C. Measles in Nigeria. Am J Dis Child. 1962 Mar;103:230–233. doi: 10.1001/archpedi.1962.02080020242007. [DOI] [PubMed] [Google Scholar]
  14. REILLY C. M., STOKES J., Jr, BUYNAK E. B., GOLDNER H., HILLEMAN M. R. Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization. N Engl J Med. 1961 Jul 27;265:165–169. doi: 10.1056/NEJM196107272650403. [DOI] [PubMed] [Google Scholar]
  15. RISTORI C., BOCCARDO H., BORGONO J. M., ARMIJO R. Medical importance of measles in Chile. Am J Dis Child. 1962 Mar;103:236–241. doi: 10.1001/archpedi.1962.02080020248009. [DOI] [PubMed] [Google Scholar]
  16. ROSEN L. Hemagglutination and hemagglutination-inhibition with measles virus. Virology. 1961 Jan;13:139–141. doi: 10.1016/0042-6822(61)90042-3. [DOI] [PubMed] [Google Scholar]
  17. STOKES J., Jr, HILLEMAN M. R., WEIBEL R. E., BUYNAK E. B., HALENDA R. Persistent immunity following Enders live, attenuated measles-virus vaccine given with human immune globulin. N Engl J Med. 1962 Aug 2;267:222–224. doi: 10.1056/NEJM196208022670503. [DOI] [PubMed] [Google Scholar]
  18. STOKES J., Jr, WEIBEL R., HALENDA R., REILLY C. M., HILLEMAN M. R. Enders' live measles-virus vaccine with human immune globulin. I. Clinical reactions. Am J Dis Child. 1962 Mar;103:366–372. doi: 10.1001/archpedi.1962.02080020378037. [DOI] [PubMed] [Google Scholar]
  19. TANEJA P. N., GHAI O. P., BHAKOO O. N. Importance of measles to India. Am J Dis Child. 1962 Mar;103:226–229. doi: 10.1001/archpedi.1962.02080020238006. [DOI] [PubMed] [Google Scholar]
  20. WEIBEL R., HALENDA R., STOKES J., Jr, HILLEMAN M. R., BUYNAK E. B. Administration of Enders' live measles virus vaccine with human immune globulin. JAMA. 1962 Jun 30;180:1086–1094. doi: 10.1001/jama.1962.03050260008002. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES